FIDO was a multicentred randomized, open-label trial that compared fixed-dose UFH with
fixed-dose LMWH for initial treatment of VTE. Patients were followed for 3 months during
which they received warfarin (target INR 2.0-3.0).
Phase:
Phase 3
Details
Lead Sponsor:
Hamilton Health Sciences Corporation McMaster University
Collaborators:
Heart and Stroke Foundation of Canada Heart and Stroke Foundation of Ontario